Vancomycin derivatives active against resistant bacterial nosocomial infections (2010–2012)

Bacterial infection is a leading cause of death worldwide and the emergence of 'superbugs' that are resistant to multiple treatments is becoming a major global concern. Vancomycin is the drug of last resort for the treatment of hospital- acquired Gram-positive bacterial infections. We will synthetically modify vancomycin by incorporating naturally occurring membrane-associative peptides to produce novel antibiotics with multiple modes of action to avoid existing bacterial resistance mechanisms.
Grant type:
NHMRC Project Grant
Funded by:
National Health and Medical Research Council